Islamabad: Lucky Core Industries Limited (LCI) reported a 4% year-over-year rise in earnings per share (EPS) to Rs25.2 for the fiscal year 2025, driven largely by a resurgence in its pharmaceutical division. The company held a briefing yesterday to discuss its annual performance and future projections.

Reduced demand for soda ash and polyester impacted overall revenue growth, which was partially mitigated by the positive performance of other business segments.

The pharmaceutical sector experienced a significant recovery, with sales surging 72% year-over-year to Rs21 billion. This includes Rs7.2 billion contributed by the recently acquired Pfizer portfolio. Profit margins in this segment reached 38%.

LCI's management anticipates maintaining a dividend payout ratio of approximately 50% and emphasized a focus on cost reduction measures in fiscal year 2026. The corporation remains debt-free, offering flexibility for strategic acquisitions. Executives project the pharmaceutical business to be the fastest-growing segment in the upcoming fiscal year.